Jasper Therapeutics(JSPR) GlobeNewswire·2025-03-01 17:45Core Insights - Jasper Therapeutics is presenting updated clinical data for briquilimab, an antibody therapy targeting c-Kit for mast cell driven diseases, at the AAAAI 2025 Annual Meeting [1][2] - The BEACON study shows briquilimab is well tolerated with a favorable safety profile, supporting its advancement into a registrational program for chronic spontaneous urticaria (CSU) [2][3] - The company plans to initiate a Phase 2b operationally adaptive study in the second half of 2025, with additional data expected mid-year 2025 to inform dose selection [2][3] Clinical Data - The updated BEACON study data includes approximately one month of additional dosing and follow-up from 49 participants [2] - No new adverse events related to c-Kit blockade were observed, reinforcing the safety profile of briquilimab [2][3] - The treatment demonstrated rapid and deep clinical responses in patients with moderate to severe CSU, particularly those previously treated with omalizumab [3] Future Plans - Jasper is enrolling additional patients in the BEACON and SPOTLIGHT studies, with plans to report data from around 70 more patients treated with briquilimab doses of 180mg or higher by mid-2025 [3] - The company aims to differentiate briquilimab from other therapies in terms of onset of action, depth of response, and safety/tolerability [3] Presentation Details - The presentations at the AAAAI 2025 Annual Meeting include multiple abstracts related to briquilimab's efficacy and mechanisms of action [4][5] - Key sessions include late-breaking oral and poster presentations scheduled for March 1 and March 2, 2025 [4][5] Company Overview - Jasper Therapeutics focuses on developing briquilimab as a treatment for chronic mast cell diseases, including CSU and asthma [6] - Briquilimab works by blocking stem cell factor from binding to c-Kit, leading to mast cell depletion and addressing the inflammatory response in these diseases [6]